Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31738696 | 0.79 | PPARD (0.47) | NOS1TSHRNOS3NOS2CYP1A2 | |
| SCHEMBL23270437 | 0.79 | MAPT (0.49) | TSHRCYP1A2CYP2D6TDP1MAPT | |
| SCHEMBL7972024 | 0.75 | TSHR (0.46) | TSHRPPARDTDP1MAPTTP53 | |
| Diethyl Hydrogen Phosphate SCHEMBL2788463 | 0.74 | NOS3 (0.58) | NOS1TSHRNOS3NOS2CYP1A2 | |
| Diethyl Hydrogen Phosphate SCHEMBL28772823 | 0.71 | NOS3 (0.52) | NOS1TSHRNOS3NOS2CYP1A2 | |
| SCHEMBL4367124 | 0.69 | NOS1 (0.42) | NOS1TSHRNOS3NOS2CYP1A2 | |
| SCHEMBL161140 | 0.69 | TSHR (0.55) | TSHRCYP2C19PPARDTDP1MEN1 | |
| SCHEMBL282085 | 0.68 | TSHR (0.60) | TSHRCYP2C19PPARDTDP1MEN1 | |
| SCHEMBL3485999 | 0.68 | TSHR (0.60) | TSHRCYP2C19PPARDTDP1MEN1 | |
| SCHEMBL3889468 | 0.67 | TSHR (0.52) | TSHRCYP2C19PPARDTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3810109-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | Peloton Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3600273-A1 | CD73 INHIBITORS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183635-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | ENTPD5, NT5E, ENTPD1 | NOS1 1868/4885TSHR 2778/4885NOS3 1688/4885 |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NOS1 1553/4885TSHR 1870/4885NOS3 1791/4885 |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | NOS1 1868/4885TSHR 2778/4885NOS3 1688/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NOS1 1144/4885TSHR 986/4885NOS3 690/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NOS1 1553/4885TSHR 1870/4885NOS3 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.